A multicenter retrospective observational study of patients with generalized myasthenia gravis treated with efgartigimod

A multicenter retrospective observational study of patients with generalized myasthenia gravis treated with efgartigimod - Retrospective observational study of patients with gMG treated with efgartigimod

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060279

Enrollment

150

Registered

2026-01-07

Start date

2026-01-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

generalized myasthenia gravis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients enrolled in the specific post-marketing surveillance (PMS) study for efgartigimod intravenous (IV) formulation or subcutaneous (SC) formulation for generalized myasthenia gravis (gMG) 2)Patients who had no prior treatment with efgartigimod before enrollment in PMS

Exclusion criteria

Exclusion criteria: Patients who had prior treatment with efgartigimod before enrollment in PMS

Design outcomes

Primary

Measure	Time frame
To describe the treatment patterns and MG symptoms before and after administration of efgartigimod.	—

Secondary

Measure	Time frame
1)To describe the frequency of MG symptoms and changes in MG treatment with efgartigimod and pretreatment 2)To describe the correlation between incidence of adverse events before and after administration of efgartigimod 3)To describe changes in treatment patterns, MG symptoms, and MG treatment frequency in seropositive and double-seronegative cases treated with efgartigimod	—

Countries

Japan

Contacts

Public ContactHiromi Matsuura

Ark Medical Solutions Inc. Clinical Research

h.matsuura@arkms.com03-5979-1001

Outcome results